

Financial news for BLRX dated on 2020-06-01: BioLineRx Announces \$4.39 Million Registered Direct Offering

Financial news for BLRX dated on 2020-05-27: 96 Biggest Movers From Yesterday

Financial news for BLRX dated on 2020-05-26: Mid-Afternoon Market Update: Crude Oil Up 2%; argenx Shares Spike Higher

Financial news for BLRX dated on 2020-05-26: 61 Stocks Moving In Tuesday's Mid-Day Session

Financial news for BLRX dated on 2020-05-26: Mid-Day Market Update: Dow Jumps Over 600 Points; BioLineRx Shares Plunge

Financial news for BLRX dated on 2020-05-26: Mid-Morning Market Update: Markets Open Higher; AutoZone Beats Q3 Expectations

Financial news for BLRX dated on 2020-05-26: BioLineRx Announces \$9M Registered Direct Offering

Financial news for BLRX dated on 2020-05-26: 71 Biggest Movers From Friday

Financial news for BLRX dated on 2020-05-22: 46 Stocks Moving In Friday's Mid-Day Session

Financial news for BLRX dated on 2020-05-20: BioLine Rx Q1 EPS \$(0.040) Beats \$(0.660) Estimate

Financial news for BLRX dated on 2020-04-23: BioLineRx Shares Tick Slightly Higher On Uptick In Volume; Traders Circulate Apr. 23-Dated World Intellectual Property Organization PatentScope Doc For 'Treatment Of Metastatic Pancreatic Adenocarcinoma'

Financial news for BLRX dated on 2020-04-13: 20 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for BLRX dated on 2020-02-27: BioLineRx Reports Notice Of Allowance Of US PTO For Patent Covering BL-8040 In Combo With Anti-PD-1 For Treatment Of Any Type Of Cancer

Financial news for BLRX dated on 2020-01-22: 98 Biotechnology Stocks Moving In Wednesday's Session

Financial news for BLRX dated on 2020-01-22: 9 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for BLRX dated on 2020-01-22: 6 Biotechnology Stocks Moving In Wednesday's Pre-Market Session

Financial news for BLRX dated on 2020-01-22: BioLineRx Completes Recruitment In Triple Combination Arm Of COMBAT/KEYNOTE-202 Study In Patients With Second-line Metastatic Pancreatic Cancer

Financial news for BLRX dated on 2020-01-14: BioLineRx Receives Orphan Drug Designation For Motixafortide (BL-8040) For Treatment Of Pancreatic Cancer In Europe

Financial news for BLRX dated on 2019-12-17: 74 Biggest Movers From Yesterday

Financial news for BLRX dated on 2019-12-16: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for BLRX dated on 2019-12-13: The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer

Financial news for BLRX dated on 2019-12-13: BioLineRx Offers Updated Phase 2a Data From Triple Combo Arm Of COMBAT/KEYNOTE-202 Study In Patients With Second-line Metastatic Pancreatic Cancer

Financial news for BLRX dated on 2019-12-10: 80 Biggest Movers From Yesterday

Financial news for BLRX dated on 2019-12-09: 74 Biggest Movers From Friday

Financial news for BLRX dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for BLRX dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for BLRX dated on 2019-12-06: 75 Biggest Movers From Yesterday

Financial news for BLRX dated on 2019-12-05: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for BLRX dated on 2019-12-05: Stocks That Hit 52-Week Lows On Thursday

Financial news for BLRX dated on 2019-12-05: Mid-Morning Market Update: Markets Open Lower; Dollar General Earnings Top Expectations

Financial news for BLRX dated on 2019-12-05: BioLineRx Reports Prelim. Phase 2a Data From Triple Combo Arm Of COMBAT/KEYNOTE-202 Study In Second-Line Patients With Metastatic Pancreatic Cancer

Financial news for BLRX dated on 2019-11-14: 19 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for BLRX dated on 2019-11-13: 9 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for BLRX dated on 2019-11-11: BioLine Rx Q3 EPS \$(0.03) Beats \$(0.64) Estimate

Financial news for BLRX dated on 2019-11-05: BioLineRx Announces Data Showing BL-8040 In Combination With KEYTRUDA Shows Clinical Activity In Heavily Pretreated Metastatic Pancreatic Cancer Patients

Financial news for BLRX dated on 2019-11-05: BioLineRx Highlights Presentation Of Data From Triple Combination Of BL-8040 Anti PD-1 And Chemotherapy Demonstrating 'Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microenvironment'

Financial news for BLRX dated on 2019-10-31: BioLineRx To Present Two Posters At Society For Immunotherapy of Cancer (SITC) 2019 Nov. 6-10

Financial news for BLRX dated on 2019-10-04: 42 Biggest Movers From Yesterday

Financial news for BLRX dated on 2019-09-25: BioLineRx Announces Dosing Of First Patient In Part 2 Of Phase 1/2a Clinical Study For AGI-134, A Novel Immunotherapy For Treatment Of Solid Tumors

Financial news for BLRX dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for BLRX dated on 2019-09-04: 66 Biggest Movers From Yesterday

Financial news for BLRX dated on 2019-09-03: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for BLRX dated on 2019-09-03: 32 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for BLRX dated on 2019-09-03: 26 Stocks Moving in Tuesday's Pre-Market Session

Financial news for BLRX dated on 2019-09-03: BioLineRx Successfully Completes Dose-Escalation Part Of Phase 1/2a Clinical Study For AGI-134 Immunotherapy For Treatment Of Solid Tumors

Financial news for BLRX dated on 2019-08-09: The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2

Financial news for BLRX dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for BLRX dated on 2019-08-07: Stocks That Fell Through 52-Week Lows Wednesday

Financial news for BLRX dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for BLRX dated on 2019-08-06: BioLine Rx Q2 EPS \$(0.04) Beats \$(0.63) Estimate

Financial news for BLRX dated on 2019-07-24: The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

Financial news for BLRX dated on 2019-07-23: List of Companies Reaching Yearly Lows Tuesday

Financial news for BLRX dated on 2019-06-28: BioLineRx Announces Change In Ratio Of American Depositary Shares To Ordinary Shares

Financial news for BLRX dated on 2019-06-04: The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer

Financial news for BLRX dated on 2019-05-14: BioLineRx Ltd. Shares Q1 EPS \$(0.06) Misses \$(0.05) Estimate

Financial news for BLRX dated on 2019-05-14: BioLineRx On Track For Phase 2 Data Read-Outs In Pancreatic Cancer And Consolidation AML By Year-End 2019

Financial news for BLRX dated on 2019-05-07: BioLine RX shares are trading higher after the company announced FDA approval of its Investigational New Drug (IND) application for AGI-134, a novel immunotherapy anti-cancer vaccine for solid tumors.

Financial news for BLRX dated on 2019-05-07: BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors

Financial news for BLRX dated on 2019-05-07: BioLineRx Announces FDA Approval of its Investigational New Drug Application for AGI-134

Financial news for BLRX dated on 2019-03-28: BioLine Rx FY18 EPS \$(0.21) vs \$(0.27) YoY

Financial news for BLRX dated on 2019-03-27: BioLine Rx shares are trading higher after the company reported positive data from its Phase 3 GENESIS trial for BL-8040 in multiple myeloma patients.

Financial news for BLRX dated on 2019-03-27: BioLineRx Reports HSCs Mobilized By BL-8040 In Combo With Granulocyte Colony-Stimulating Factor Were Successfully Engrafted In All 11 Patients Participating In Part 1 Of Trial

Financial news for BLRX dated on 2019-02-08: The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

Financial news for BLRX dated on 2019-02-06: 50 Biggest Movers From Yesterday

Financial news for BLRX dated on 2019-02-05: Mid-Afternoon Market Update: Crude Oil Down 1.5%; M/I Homes Shares Spike Higher

Financial news for BLRX dated on 2019-02-05: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for BLRX dated on 2019-02-05: Mid-Day Market Update: Estee Lauder Jumps On Upbeat Earnings; Opko Health Shares Slide

Financial news for BLRX dated on 2019-02-05: Mid-Morning Market Update: Markets Open Higher; Archer Daniels Midland Earnings Miss Views

Financial news for BLRX dated on 2019-02-05: BioLineRx Prices 28M Share Offering Of ADSs And Warrants At \$0.55/Unit

Financial news for BLRX dated on 2019-02-05: BioLine Rx shares are trading lower after the company announced a proposed offering for its American depository shares and warrants.

Financial news for BLRX dated on 2019-02-05: 32 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BLRX dated on 2019-02-05: The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Financial news for BLRX dated on 2019-02-05: 56 Biggest Movers From Yesterday

Financial news for BLRX dated on 2019-02-04: BioLineRx 6-K Shows Co. Commenced Offering OF ADSs, No Size Disclosed

Financial news for BLRX dated on 2019-02-04: Mid-Afternoon Market Update: Dow Rises 100 Points; Maxwell Technologies Shares Jump Following Tesla Deal

Financial news for BLRX dated on 2019-02-04: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for BLRX dated on 2019-02-04: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for BLRX dated on 2019-02-04: BioLine Receives Orphan Drug Designation From the FDA for BL-8040 for the Treatment of Pancreatic Cancer

Financial news for BLRX dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for BLRX dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for BLRX dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for BLRX dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for BLRX dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for BLRX dated on 2018-12-14: Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018

Financial news for BLRX dated on 2018-12-11: BioLineRx Announces Initiation Of Triple Combination Arm Of Phase 2a COMBAT/KEYNOTE-202 Study In Pancreatic Cancer Under Immuno-Oncology Collaboration

Financial news for BLRX dated on 2018-11-20: BioLineRx Receives FDA Biological Product Designation For Novel Cancer Immunotherapy Candidate AGI-134

Financial news for BLRX dated on 2018-11-15: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018

Financial news for BLRX dated on 2018-11-08: BioLineRx Ltd. - American Depositary Shares Q3 EPS \$(0.06), Inline

Financial news for BLRX dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for BLRX dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for BLRX dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for BLRX dated on 2018-10-29: Stocks Which Set New 52-Week Low Friday, October 26th

Financial news for BLRX dated on 2018-10-22: 58 Biggest Movers From Friday

Financial news for BLRX dated on 2018-10-20: BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Showing BL-8040 Significantly Improves T-cell Infiltration Into the Tumor and Reduces Immunosuppression in the Tumor Microenvironment at ESMO 2018

Financial news for BLRX dated on 2018-10-19: 42 Stocks Moving In Friday's Mid-Day Session

Financial news for BLRX dated on 2018-10-19: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for BLRX dated on 2018-10-19: UPDATE: BioLineRx Says 'Triple combination expansion cohort (BL-8040 + KEYTRUDA(r) (pembrolizumab) + chemotherapy) to commence by year-end'

Financial news for BLRX dated on 2018-10-19: UPDATE: BioLineRx On Phase 2a COMBAT/KEYNOTE-202 Study: 'Encouraging results support further development of combination and expansion of collaboration'

Financial news for BLRX dated on 2018-10-19: BioLineRx Reports Top-Line Results From Phase 2a COMBAT/KEYNOTE-202 Study In Pancreatic Cancer: Combo Showed 'encouraging disease control and overall survival in patients with metastatic pancreatic cancer'

Financial news for BLRX dated on 2018-10-14: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for BLRX dated on 2018-10-05: Stocks Which Set New 52-Week High Yesterday, October 4th

Financial news for BLRX dated on 2018-10-05: The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

Financial news for BLRX dated on 2018-10-03: BioLineRx Raises Stake In Its Oncology Platform, BL-8040, From 60% To 80%

Financial news for BLRX dated on 2018-08-13: Bioline Rx Q2 EPS \$(0.05) Beats \$(0.06) Estimate

Financial news for BLRX dated on 2018-08-07: BioLineRx Reports The First 11 Patients In BL-8040 In Combination With Standard Treatment Is Safe And Tolerable And That 9/11 Patients Reached Primary Endpoint

Financial news for BLRX dated on 2018-08-01: BioLineRx Initiates Phase 1/2a Clinical Study For AGI-134, A Novel Immunotherapy For Treatment Of Solid Tumors

Financial news for BLRX dated on 2018-07-30: Benzinga Pro's 5 Stocks To Watch Today

Financial news for BLRX dated on 2018-07-30: BioLineRx Expands its Immuno-Oncology Collaboration in Pancreatic Cancer with Merck

Financial news for BLRX dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for BLRX dated on 2018-07-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for BLRX dated on 2018-06-18: BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients

Financial news for BLRX dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for BLRX dated on 2018-05-22: BioLineRx Ltd. - American Depositary Shares Q1 EPS \$(0.06) Beats \$(0.07) Estimate

Financial news for BLRX dated on 2018-05-22: Earnings Scheduled For May 22, 2018

Financial news for BLRX dated on 2018-05-17: BioLineRx Claims BL-8040 In Combination With Cytarabine Showed Significantly Improved Overall Survival Compared With Historical Data

Financial news for BLRX dated on 2018-05-17: 41 Biggest Movers From Yesterday

Financial news for BLRX dated on 2018-05-16: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for BLRX dated on 2018-05-16: BioLine Rx Shares Up 12.3% Premarket After Co. Received Grant Of European Patent Covering Use Of BL-8040 With Cytarabine For Treating Acute Myeloid Leukemia

Financial news for BLRX dated on 2018-05-16: Benzinga Pro's 5 Stocks To Watch Today

Financial news for BLRX dated on 2018-05-16: BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia

Financial news for BLRX dated on 2018-03-26: BioLineRx Reports Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors

Financial news for BLRX dated on 2018-03-06: BioLineRx Reports FY EPS \$(0.27) vs \$(0.28) Est., No Sales

Financial news for BLRX dated on 2018-01-23: BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells

Financial news for BLRX dated on 2018-01-17: UPDATE: BioLineRx Says BL-8040 'Data to be presented at the upcoming ASCO-GI conference; topline clinical results expected by H2 2018 as planned'

Financial news for BLRX dated on 2018-01-17: BioLineRx Reports Partial Monotherapy Results From Phase 2a COMBAT Study In Pancreatic Cancer: 'BL-8040 monotherapy resulted in increased infiltration of T cells into tumor'

Financial news for BLRX dated on 2017-12-29: 5 Stocks To Watch For December 29, 2017

Financial news for BLRX dated on 2017-12-28: BioLineRx F-3 Filing Shows Registration For \$150M Mixed Securities Shelf Offering

Financial news for BLRX dated on 2017-12-21: 35 Stocks Moving In Thursday's Pre-Market Session

Financial news for BLRX dated on 2017-12-21: BioLineRx Reports Initiation Of Phase 3 GENESIS Trial In Stem-Cell Mobilization For Autologous Transplantation In Multiple Myeloma Patients

Financial news for BLRX dated on 2017-12-04: Oppenheimer Out Positive On BioLineRx, Says That 38% Response Rate Reported At ASH 2016 May Now Be Translating Into Survival Benefit For Patients; Believes 11.1 Median Overall Survival Observed In Cohort Is Respectable; Reiterates Outperform and \$3 PT

Financial news for BLRX dated on 2017-12-04: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for BLRX dated on 2017-12-04: BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

Financial news for BLRX dated on 2017-11-21: BioLineRx Reports Q4 EPS \$(0.07) vs \$(0.09) Est., No Sales

Financial news for BLRX dated on 2017-11-02: BioLineRx Shares Down 2% Despite Earlier News Co. To Give Oral Presentation At ASH Showing Data Supporting BL-8040 As Robust Mobilizer Of HSC Associated With Long-Term Engraftment

Financial news for BLRX dated on 2017-10-31: BioLine RX Reports At-The-Market Sales Agreement Related To Co.'s ADS's of Up To \$30M

Financial news for BLRX dated on 2017-10-18: BioLineRx Reports Initiation Of Phase 1b/2 Trial For BL-8040 In Gastic Cancer Under Immunotherapy Collaboration

Financial news for BLRX dated on 2017-09-26: BioLineRx Reports Start of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Partnership

Financial news for BLRX dated on 2017-08-21: BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization, Expects Study to Begin in 2017

Financial news for BLRX dated on 2017-08-08: BioLineRx Reports Q2 EPS \$(0.07) vs \$(0.06) Est.

Financial news for BLRX dated on 2017-08-04: Oppenheimer Initiates Coverage On BioLineRx Ltd. - American Depositary Shares with Outperform Rating, Announces \$3.00 Price Target

Financial news for BLRX dated on 2017-07-26: BioLineRx Reports Added, Direct \$9.6M Investment From BVF Partners

Financial news for BLRX dated on 2017-07-05: Companies Holding Shareholder Meetings Today Include BioLineRX and Fortuna Silver Mines

Financial news for BLRX dated on 2017-05-25: BioLineRx Reports Q1 EPS \$(0.08) vs \$(0.06) Est.

Financial news for BLRX dated on 2017-05-18: Benzinga's Top Upgrades, Downgrades For May 18, 2017

Financial news for BLRX dated on 2017-05-18: Maxim Group Upgrades BioLineRx Ltd. - American Depositary Shares to Buy

Financial news for BLRX dated on 2017-03-31: Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher

Financial news for BLRX dated on 2017-03-31: 15 Biggest Mid-Day Losers For Friday

Financial news for BLRX dated on 2017-03-31: Mid-Day Market Update: Sorl Auto Parts Rises After Q4 Results; Bioline RX Shares Drop

Financial news for BLRX dated on 2017-03-31: Mid-Morning Market Update: Markets Edge Lower; BlackBerry Earnings Top Views

Financial news for BLRX dated on 2017-03-31: BioLineRx Prices 29.4M ADS At \$0.85/ADS

Financial news for BLRX dated on 2017-03-31: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for BLRX dated on 2017-03-30: BioLineRx Reports Underwritten Public Offering Of American Depositary SHares

Financial news for BLRX dated on 2017-03-23: BioLineRx FY 2016 EPS \$(0.28) vs \$(0.08) Est, No Sales

Financial news for BLRX dated on 2017-03-23: BioLineRx Announces Acquisition of Agalimmune Ltd. For \$6M Upfront Payment Compromised Of \$3M Cash And Remainder In BioLineRx Shares

Financial news for BLRX dated on 2017-03-20: BioLineRx Says It Expects Top-Line Results For BL-8040 By End Of 2017

Financial news for BLRX dated on 2017-02-13: Rodman & Renshaw Initiates Coverage On BioLineRx Ltd. at Buy, \$3 Price Target

Financial news for BLRX dated on 2017-01-17: BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA

Financial news for BLRX dated on 2016-12-05: 15 Biggest Mid-Day Gainers For Monday

Financial news for BLRX dated on 2016-12-05: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for BLRX dated on 2016-12-05: BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

Financial news for BLRX dated on 2016-11-21: BioLineRx Signs Exclusive Agreement With Yissum Research Development Company

Financial news for BLRX dated on 2016-11-03: BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

Financial news for BLRX dated on 2016-10-06: BioLineRx Regains Nasdaq \$1 Minimum Bid Price Requirement

Financial news for BLRX dated on 2016-10-05: BioLineRx Reports Acceptance of BL-8040 Abstracts for Oral, Poster Presentations at ASH Meeting

Financial news for BLRX dated on 2016-09-23: 18 Biggest Mid-Day Gainers For Friday

Financial news for BLRX dated on 2016-09-23: Mid-Day Market Update: Twitter Surges On Takeover Rumor; Enphase Energy Shares Drop

Financial news for BLRX dated on 2016-09-23: Mid-Morning Market Update: Markets Open Lower; Finish Line Sales Beat Views

Financial news for BLRX dated on 2016-09-23: BioLineRx Reports In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration

Financial news for BLRX dated on 2016-09-20: BioLineRx Reports Start of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA for Treatment of Pancreatic Cancer

Financial news for BLRX dated on 2016-09-08: BioLineRx Phase 2a Trial Shows Complete Remission Rate Was 38% In 2 Cycles of BL-8040 Treatment, 1.5mg/kg Dose Selected For Expansion Phase Of Study Showed Complete Remission Rate Of 41%

Financial news for BLRX dated on 2016-09-07: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for BLRX dated on 2016-09-07: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for BLRX dated on 2016-09-07: BioLineRx +13.3% Preamarket @\$1.02; Co Announced Collaboration to Investigate Combination of BL-8040 with Atezolizumab

Financial news for BLRX dated on 2016-09-07: BioLineRx To Collaborate With Roche on Several Phase 1b Studies

Financial news for BLRX dated on 2016-08-25: BioLineRx, I-Bridge Capital Establish a New Drug Development Joint Venture in China

Financial news for BLRX dated on 2016-08-12: Maxim Group Downgrades BioLine Rx to Hold

Financial news for BLRX dated on 2016-08-11: BioLineRx Reports Q2 EPS \$(0.09) vs \$(0.07) Est.

Financial news for BLRX dated on 2016-08-11: BioLineRx Reports Q2 EPS \$(0.07) vs. Est. \$(0.07)

Financial news for BLRX dated on 2016-08-11: BioLineRx Names Philip Serlin CEO

Financial news for BLRX dated on 2016-08-08: BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer

Financial news for BLRX dated on 2016-06-28: BioLineRx Reports Regulatory Submissions for Phase 2a Trial of BL-8040 in Combo with KEYTRUDA for Treatment of Pancreatic Cancer

Financial news for BLRX dated on 2016-05-17: BioLineRx Reports Q1 EPS \$(0.064) vs \$(0.101) in Same Qtr. Last Year

Financial news for BLRX dated on 2016-05-17: Earnings Scheduled For May 17, 2016

Financial news for BLRX dated on 2016-04-04: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for BLRX dated on 2016-04-04: BioLineRx +13% Premarkrt @\$1.11 as Co Reports Novel Treatment for Non-Surgical Removal of Skin Lesions Received CE Mark Approval

Financial news for BLRX dated on 2016-04-04: BioLineRx Reports Novel Treatment for Non-Surgical Removal of Skin Lesions Received CE Mark Approval

Financial news for BLRX dated on 2016-03-29: BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML, Identifies Future Biomarker

Financial news for BLRX dated on 2016-03-23: BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment

Financial news for BLRX dated on 2016-01-25: BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment

Financial news for BLRX dated on 2016-01-12: BioLineRx, MSD Investigate Combination of Keytruda And BL-8040 In Pancreatic Cancer

Financial news for BLRX dated on 2015-12-14: BioLineRx Reports Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment

Financial news for BLRX dated on 2015-11-23: BioLineRx Reports Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions

Financial news for BLRX dated on 2015-11-16: BioLine RX Reports Q3 EPS \$(0.02) vs Est \$(0.08)

Financial news for BLRX dated on 2015-11-16: Earnings Scheduled For November 16, 2015

Financial news for BLRX dated on 2015-11-05: BioLineRx Announces Positive Clinical Results from First Part of Phase 2 Trial in r/r AML

Financial news for BLRX dated on 2015-09-10: BioLineRx Reports Regulatory Submission fo Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome, Aplastic Anemia

Financial news for BLRX dated on 2015-09-03: BioLineRx to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York

Financial news for BLRX dated on 2015-08-17: BioLineRx Reports Beginning of Phase 2b Trial for Novel AML Consolidation Treatment

Financial news for BLRX dated on 2015-07-27: Market Update: Monday's Mid-Day Movers, China's Stock Market Crash And More

Financial news for BLRX dated on 2015-07-27: Morning Market Losers

Financial news for BLRX dated on 2015-07-16: BioLineRx Investors: Expect 'Pivotal' Data In Next Few Weeks

Financial news for BLRX dated on 2015-06-22: JP Morgan: BioLineRx Will Outperform, Is Worth \$5/Share On 'Promising Technology'

Financial news for BLRX dated on 2015-06-22: Benzinga's Top Initiations

Financial news for BLRX dated on 2015-06-22: JMP Securities Initiates Coverage on Bioline Rx at Outperform, Announces \$5.00 PT

Financial news for BLRX dated on 2015-06-22: JP Morgan Initiates Bioline RX With Market Outperform

Financial news for BLRX dated on 2015-06-22: JP Morgan Initiates Coverage on Bioline Rx at Market Outperform, Announces \$5.00 PT

Financial news for BLRX dated on 2015-06-17: BioLineRx Says Will Present Successful Results of Phase 1/2 Study of Novel Celiac Treatment

Financial news for BLRX dated on 2015-06-15: BioLineRx Presents Positive Safety, Efficacy Results for Novel Stem-Cell Mobilization Treatment at European Hematology Association Conference

Financial news for BLRX dated on 2015-06-03: Research Underlying BioLineRx's Treatment of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award

Financial news for BLRX dated on 2015-06-01: BioLineRx Reports Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin Lesions

Financial news for BLRX dated on 2015-05-27: BioLineRx Announces Will Present Safety, Efficacy Clinical Data for Novel Stem Cell Mobilization Treatment at EHA

Financial news for BLRX dated on 2015-05-18: BioLine Reports Q1 Loss \$0.01 Vs Exp Loss \$0.06

Financial news for BLRX dated on 2015-05-18: Earnings Scheduled For May 18, 2015

Financial news for BLRX dated on 2015-05-05: Analysts Like Bioline RX After Trial Hits 'Expansion Stage'

Financial news for BLRX dated on 2015-05-04: BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for AML

Financial news for BLRX dated on 2015-05-04: BioLineRx Begins Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia

Financial news for BLRX dated on 2015-04-08: 5 Biotech Stocks Roth Capital Analysts Are Watching

Financial news for BLRX dated on 2015-03-11: BioLineRx's BL-9020 for Type 1 Diabetes Effective in Preclinical Trials

Financial news for BLRX dated on 2015-03-09: Morning Market Gainers

Financial news for BLRX dated on 2015-03-09: Benzinga's Top #PreMarket Gainers

Financial news for BLRX dated on 2015-03-09: BioLineRx Shares Rise 6.5% Premarket; Co Presenting Tuesday at Roth Conference

Financial news for BLRX dated on 2015-03-06: Morning Market Losers

Financial news for BLRX dated on 2015-03-02: BioLineRx Files Regulatory Submission for Phase 2b Trial of BL-8040

Financial news for BLRX dated on 2015-01-14: BioLineRx Announces Completion of Enrollment in CE Mark Registration Trial of BL-1040

Financial news for BLRX dated on 2014-12-22: Novartis Reports 12.8% Passive Stake in BioLineRx as of December 16

Financial news for BLRX dated on 2014-12-16: Morning Market Movers

Financial news for BLRX dated on 2014-12-16: Benzinga's Top #PreMarket Gainers

Financial news for BLRX dated on 2014-12-16: UPDATE: Bioline RX Said Novartis Made \$10M Initial Investment for ~12.8% of Co., Has Option to Pay \$5M Fee, Could Fund 50% of Development Costs

Financial news for BLRX dated on 2014-12-16: UPDATE: BioLine RX Shares Rise 20% Premarket on Announcement of Strategic Collaboration Agreement With Novartis

Financial news for BLRX dated on 2014-12-08: Morning Market Movers

Financial news for BLRX dated on 2014-12-08: BioLineRx Announces Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference

Financial news for BLRX dated on 2014-10-31: US Stock Futures Signal Higher Start On Wall Street

Financial news for BLRX dated on 2014-10-31: BioLineRx Announces Publication of Results from Previous Phase 1/2 Trial of BL-1040; Expecting Study Completion Mid '15

Financial news for BLRX dated on 2014-09-03: BioLineRx Announces Dosing of First Patient for BL-8040's Second Indication as Novel Stem Cell Mobilization Treatment

Financial news for BLRX dated on 2014-08-21: BioLineRx Receives Notice of Allowance for US Patent on BL-7010 Covering Use of Novel Polymer in Prevention of Gluten Toxicity

Financial news for BLRX dated on 2014-07-16: BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment

Financial news for BLRX dated on 2014-05-30: BioLine RX Shares Edge Higher Following News of Deal to Buy \$20M in Shares with Lincoln Park

Financial news for BLRX dated on 2014-04-10: BioLineRx Announces Investigator-Initiated Study for Novel CML Treatment

Financial news for BLRX dated on 2014-03-14: US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report

Financial news for BLRX dated on 2014-03-14: BioLineRx Awarded US Patent Covering Use of BL-8040 in Immunotherapy

Financial news for BLRX dated on 2014-03-10: Zix Corporation, Bio Light Israeli Life Sciences, Power Solutions International, Sapiens, Cytokinetics, BioLineRx, Arotech, FX Energy, Cherokee Presenting at Roth Conference at 12:00 PM ET

Financial news for BLRX dated on 2014-03-10: BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment

Financial news for BLRX dated on 2014-01-23: BioLineRx Receives FDA Orphan Drug Designation for BL-8040

Financial news for BLRX dated on 2013-12-10: BioLineRx Presents Positive Preclinical Results of AML Treatment at ASH

Financial news for BLRX dated on 2013-11-26: BioLineRx Announces Positive Phase 2a Trial Results for Orally Available IBD Treatment

Financial news for BLRX dated on 2013-11-19: US Stock Futures Edge Lower Ahead Of Earnings

Financial news for BLRX dated on 2013-11-19: BioLineRx Reports Publication of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma

Financial news for BLRX dated on 2013-11-04: BioLineRx Receives Regulatory Finnish Approval for BL-7010 Phase 1/2 Safety Trial

Financial news for BLRX dated on 2013-10-23: BioLineRx Announces Worldwide Licensing Agreement for BL-9020 for Treatment of Type 1 Diabetes

Financial news for BLRX dated on 2013-10-23: BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes

Financial news for BLRX dated on 2013-09-24: BioLineRx Files Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease

Financial news for BLRX dated on 2013-09-17: BioLineRx Issued Notice of Allowance by USPTO for Patent on Use of BL-8020 Treatment for Hepatitis C

Financial news for BLRX dated on 2013-06-10: BioLineRx Enters into Collaboration on Hepatitis C Drug with CTTQ

Financial news for BLRX dated on 2013-05-17: Bioline RX May Sell Up to \$20M in ADSs

Financial news for BLRX dated on 2013-04-17: A Peek Into The Market Before The Trading Starts

Financial news for BLRX dated on 2013-04-17: BioLineRx Announces Positive Phase II Results for BL-7040

Financial news for BLRX dated on 2013-04-10: Morning Market Movers

Financial news for BLRX dated on 2013-04-10: BioLineRx Receives Regulatory Approval for Phase II Clinical Trial for BL-8040 Leukemia Treatment

Financial news for BLRX dated on 2013-03-20: Stocks Hitting 52-Week Lows

Financial news for BLRX dated on 2013-03-20: BioLineRx Shares Resume Trading Down

50+%

Financial news for BLRX dated on 2013-03-20: BioLineRx Shares to Resume Trading at 9:50AM EST

Financial news for BLRX dated on 2013-03-20: BioLineRX Says CLARITY Trial of BL-1020 Did Not Meet Primary Efficacy Endpoint, to Discontinue Study

Financial news for BLRX dated on 2013-03-20: BioLine RX Halted News Pending

Financial news for BLRX dated on 2013-03-13: A Peek Into The Market Before The Trading Starts

Financial news for BLRX dated on 2013-03-13: BioLineRx Gets Approval from French Regulatory Authorities for Phase I/II Clinical Trial for BL-8020 for Hepatitis C

Financial news for BLRX dated on 2013-03-12: BiolineRX Moves Higher; May be Related to Globes Article on Hep C Drug Development Deal

Financial news for BLRX dated on 2013-02-04: BioLineRx Clarifies Interim Analysis of CLARITY Trial for BL-1020

Financial news for BLRX dated on 2013-01-15: Benzinga's Small Cap Movers for Tuesday January 15, 2013

Financial news for BLRX dated on 2013-01-07: BioLineRx to Report Interim Results of Phase II/III Trial for Schizophrenia Drug BL-1020 During Week of March 18, 2013

Financial news for BLRX dated on 2012-10-24: BioLineRx to Conduct Interim Analysis of Phase II/III CLARITY Trial of BL-1020

Financial news for BLRX dated on 2012-10-16: BioLineRx Announces Successful Completion of Pre-Clinical Development for BL-8020 Hepatitis C Treatment

Financial news for BLRX dated on 2012-10-09: BioLineRx Announces EAGLE Phase IIb Study Shows Significantly Greater Beneficial Effect of BL-1020 on Cognitive Function in Schizophrenia Patients

Financial news for BLRX dated on 2012-10-03: Morning Market Movers

Financial news for BLRX dated on 2012-09-27: A Peek Into The Market Before The Trading Starts

Financial news for BLRX dated on 2012-09-27: BioLineRx Enters into Share Purchase Agreement with Lincoln Park Capital for \$15M of ADSs

Financial news for BLRX dated on 2012-09-27: BioLineRx EAGLE Study Report Results Demonstrating BL-1020's Efficacy in Improving Cognitive Function in Schizophrenia Patients

Financial news for BLRX dated on 2012-09-24: BioLineRx Receives Notice of Allowance from USPTO

Financial news for BLRX dated on 2012-09-10: BioLineRx Announces Pre-clinical Results Demonstrating the Safety of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity

Financial news for BLRX dated on 2012-08-10: BiolineRx Files to Offer up to \$75 Million in Mixed-Securities

Financial news for BLRX dated on 2012-07-09: BioLineRx Receives Notice of Intention to Grant Additional European Patent Covering BL-1020, for the Treatment of Schizophrenia

Financial news for BLRX dated on 2012-06-05: BioLineRx Announces Receipt of Two Notices of Allowance from USPTO for Patents Covering BL-1021

Financial news for BLRX dated on 2012-03-05: BioLineRx Receives Approval for Commencing Phase II Clinical Trial of BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease

Financial news for BLRX dated on 2012-02-29: Financial Breakfast: Morning News Summary for February 29, 2012

Financial news for BLRX dated on 2012-02-29: BioLineRx Announces Receipt of Notice of Allowance from USPTO for Patent Covering BCM

Financial news for BLRX dated on 2012-02-21: From Earlier: BioLineRx Announces Publication of Pre-Clinical Results Demonstrating Efficacy of BL-7010

Financial news for BLRX dated on 2012-02-16: BioLineRx to Place \$15 Million in Securities with Institutional Investors

Financial news for BLRX dated on 2012-02-07: Thinly Traded BioLineRx Shares Move on Hepatitis C Deal

Financial news for BLRX dated on 2012-02-06: BioLineRx Rises 17% on Licensing Agreement

Financial news for BLRX dated on 2012-02-06: Financial Breakfast: Morning News Summary for February 06, 2012

Financial news for BLRX dated on 2012-02-06: BioLineRx In-Licenses Second Oral Hepatitis C Treatment

Financial news for BLRX dated on 2012-01-25: Hepatitis C Pill Race Makes BioLineRx a Buyout Target: Israel Overnight -Bloomberg

Financial news for BLRX dated on 2012-01-24: Benzinga's Microcap Movers for Tuesday January 24, 2012

Financial news for BLRX dated on 2012-01-24: BioLineRx Trading 99.1% Higher on Heavy Volume; Currently at \$6.55

Financial news for BLRX dated on 2012-01-24: BioLineRx Trading 71.1% Higher on Heavy Volume; Currently at \$5.63

Financial news for BLRX dated on 2012-01-24: BioLineRX Deal With Genoscience, Key Personnel All Under 35-Years Old, Shares Moving Lower

Financial news for BLRX dated on 2012-01-24: BioLineRx Surges after Hep C License Agreement

Financial news for BLRX dated on 2012-01-24: BioLineRx Rises 58% on Hep C Licensing Agreement

Financial news for BLRX dated on 2012-01-24: BioLineRx Rises 16% on Licensing Agreement

Financial news for BLRX dated on 2012-01-24: BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C

Financial news for BLRX dated on 2012-01-03: BioLineRx Announces Initiation of CE Mark Registration Trial for BCM

Financial news for BLRX dated on 2011-12-13: BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen

Financial news for BLRX dated on 2011-12-06: BioLineRx Announces Positive Final Results from Phase Ia Clinical Trial of BL-1021 for Neuropathic Pain

Financial news for BLRX dated on 2011-11-22: Financial Breakfast: Morning News Summary for November 22, 2011

Financial news for BLRX dated on 2011-11-22: BioLineRx Announces Receipt of Approval in India to Commence Phase II/III CLARITY Clinical Trial of BL-1020 for Treatment of Schizophrenia

Financial news for BLRX dated on 2011-09-27: BioLineRx to Present Data from Phase IIb Trial of BL-1020

Financial news for BLRX dated on 2011-09-15: BioLineRx Announces European Confirmation of Medical Device Regulatory Pathway for BL-5010, for Non-surgical Removal of Skin Lesions

Financial news for BLRX dated on 2011-09-13: Morning Market Movers

Financial news for BLRX dated on 2011-09-13: BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain

Financial news for BLRX dated on 2011-09-07: Morning Market Losers

Financial news for BLRX dated on 2011-09-07: BioLineRx In-Licenses BL-7050, a Novel, Orally-Available Molecule for the Treatment of Neuropathic and Inflammatory Pain

Financial news for BLRX dated on 2011-07-25: BioLineRx ADRs Begin Trading on NASDAQ